
<SEC-DOCUMENT>0001102624-16-003244.txt : 20160810
<SEC-HEADER>0001102624-16-003244.hdr.sgml : 20160810
<ACCEPTANCE-DATETIME>20160810125145
ACCESSION NUMBER:
CONFORMED SUBMISSION TYPE:
PUBLIC DOCUMENT COUNT:
CONFORMED PERIOD OF REPORT:
FILED AS OF DATE:
DATE AS OF CHANGE:
6-K
2
20160809
0001102624-16-003244
20160810
20160810
FILER:
COMPANY DATA:
COMPANY CONFORMED NAME:
CENTRAL INDEX KEY:
STANDARD INDUSTRIAL CLASSIFICATION: GOLD & SILVER ORES [1040]
IRS NUMBER:
STATE OF INCORPORATION:
FISCAL YEAR END:
REPLICEL LIFE SCIENCES INC.
0001205059
000000000
1231
A1
FILING VALUES:
FORM TYPE:
SEC ACT:
SEC FILE NUMBER: 000-50112
FILM NUMBER:
6-K
1934 Act
161820755
BUSINESS ADDRESS:
STREET 1:
CITY:
STATE:
ZIP:
BUSINESS PHONE:
MAIL ADDRESS:
STREET 1:
CITY:
STATE:
ZIP:
FORMER COMPANY:
SUITE 900 - 570 GRANVILLE STREET
VANCOUVER BC
A1
V6C 3P1
604-248-8693
SUITE 900 - 570 GRANVILLE STREET
VANCOUVER BC
A1
V6C 3P1
FORMER CONFORMED NAME: NEWCASTLE RESOURCES LTD.
DATE OF NAME CHANGE:
20081128
FORMER COMPANY:
FORMER CONFORMED NAME: PAN AMERICAN GOLD CORP
DATE OF NAME CHANGE:
20040521
FORMER COMPANY:
FORMER CONFORMED NAME: TRI LATERAL VENTURE CORP
DATE OF NAME CHANGE:
20021109
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>replicel6k.htm
<DESCRIPTION>REPLICEL LIFE SCIENCES INC. 6-K
<TEXT>
<html>
<head>
<title></title>
<!--Licensed to: Marketwired
    Document created using EDGARfilings PROfile 4.1.0.0
    Copyright 1995 - 2016 Summit Financial Printing, LLC.  All rights 
reserved.-->
</head>
<body style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt" 
bgcolor="#ffffff" text="#000000">
<div>
<hr style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center; BACKGROUND-COLOR:
#ffffff; HEIGHT: 10px; COLOR: #ffffff; MARGIN-LEFT: auto; BORDER-TOP: black 4px 
solid; MARGIN-RIGHT: auto">
</div>
<div>&#160;</div>
<div><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">&#160; 
</font>
<div style="TEXT-ALIGN: center; LINE-HEIGHT: 13.7pt; MARGIN-TOP: 12pt; FONT-
FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">UNITED 
STATES</div>
<div style="TEXT-ALIGN: center; LINE-HEIGHT: 13.7pt; FONT-FAMILY: 'Times New 
Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">SECURITIES AND EXCHANGE 
COMMISSION</div>
<div style="TEXT-ALIGN: center; LINE-HEIGHT: 13.7pt; FONT-FAMILY: 'Times New 
Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Washington, D.C.&#160; 20549</div>
<div style="TEXT-ALIGN: center; LINE-HEIGHT: 13.7pt; MARGIN-TOP: 12pt; FONT-
FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Form 6-K</div>
<div style="TEXT-ALIGN: center; LINE-HEIGHT: 13.7pt; MARGIN-TOP: 12pt; FONT-
FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">REPORT OF FOREIGN
PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE 
ACT OF 1934</div>
<div style="TEXT-ALIGN: justify; LINE-HEIGHT: 13.7pt; MARGIN-TOP: 12pt; FONT-
FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">For the month of&#160;<font 
style="FONT-VARIANT: normal; FONT-STYLE: normal; FONT-FAMILY: 'Times New Roman';
FONT-SIZE: 10pt; FONT-WEIGHT: normal"><u>August 2016</u></font></div>
<div style="TEXT-ALIGN: justify; LINE-HEIGHT: 12.55pt; MARGIN-TOP: 12pt; FONT-
FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Commission File Number <u>000-
</u><u>50112</u></div>
<div style="TEXT-ALIGN: center; LINE-HEIGHT: 13.7pt; MARGIN-TOP: 12pt; FONT-
FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><u>RepliCel Life 
Sciences Inc.</u></div>
<div style="TEXT-ALIGN: center; LINE-HEIGHT: 13.7pt; FONT-FAMILY: 'Times New 
Roman'; FONT-SIZE: 10pt">(Translation of registrant&#8217;s name into 
English)</div>
<div style="TEXT-ALIGN: center; LINE-HEIGHT: 13.7pt; MARGIN-TOP: 12pt; FONT-
FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><u>Suite 2020 
&#8211; 401 West Georgia Street, Vancouver, British Columbia&#160; V6B 
5A1</u></div>
<div style="TEXT-ALIGN: center; LINE-HEIGHT: 13.7pt; FONT-FAMILY: 'Times New 
Roman'; FONT-SIZE: 10pt">(Address of principal executive office)</div>
<div style="TEXT-ALIGN: justify; LINE-HEIGHT: 13.7pt; MARGIN-TOP: 12pt; FONT-
FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Indicate by check mark whether the 
registrant files or will file annual reports under cover of Form 20-F or Form 
40-F.&#160; &#160;&#160; Form 20-F&#160;&#160;[X]&#160; Form 40-F&#160;&#160;
[&#160; ]</div>
<div style="TEXT-ALIGN: justify; LINE-HEIGHT: 13.7pt; MARGIN-TOP: 12pt; FONT-
FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Indicate by check mark if the 
registrant is submitting the Form 6-K in paper as permitted by Regulation S-T 
Rule 101(b)(1) &#160;[&#160; ]</div>
<div style="TEXT-ALIGN: justify; LINE-HEIGHT: 13.7pt; MARGIN-TOP: 12pt; FONT-
FAMILY: 'Times New Roman'; FONT-SIZE: 10pt"><font style="FONT-WEIGHT: 
bold">Note:&#160; </font>Regulation S-T Rule 101(b)(1) only permits the 
submission in paper of a Form 6-K if submitted solely to provide an attached 
annual report to security holders.</div>
</div>
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">&#160;</div>
<div style="MARGIN-TOP: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-BOTTOM: 
10pt; CLEAR: both; FONT-SIZE: 10pt" id="DSPFPageBreakArea">
<div style="PAGE-BREAK-AFTER: always" id="DSPFPageBreak">
<hr style="BORDER-RIGHT-WIDTH: 0px; BACKGROUND-COLOR: #000000; MARGIN: 4px 0px; 
WIDTH: 100%; BORDER-TOP-WIDTH: 0px; BORDER-BOTTOM-WIDTH: 0px; HEIGHT: 2px; 
COLOR: #000000; CLEAR: both; BORDER-LEFT-WIDTH: 0px" noshade="noshade">
</div>
</div>
<div style="TEXT-ALIGN: center; LINE-HEIGHT: 12.55pt; MARGIN-TOP: 12pt; FONT-
FAMILY: Calibri, sans-serif; FONT-SIZE: 11pt; FONT-WEIGHT: bold"><u><br>
<font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">SUBMITTED 
HEREWITH</font></u><br style="LINE-HEIGHT: 12.55pt">
</div>
<div style="TEXT-ALIGN: justify; LINE-HEIGHT: 12.55pt; MARGIN-TOP: 12pt"><a 
href="exh99_1.htm#Exhibit99.1">99.1</a><font style="WIDTH: 36pt; DISPLAY: 
inline-block; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt" 
id="TRGRRTFtoHTMLTab">&#160;</font>REPLICEL LIFE SCIENCES SHARE CONSOLIDATION 
APPROVED
<div id="DSPFPageFooter"></div>
<div style="LINE-HEIGHT: 12.55pt">&#160;</div>
</div>
<div style="MARGIN-TOP: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-BOTTOM: 
10pt; CLEAR: both; FONT-SIZE: 10pt" id="DSPFPageBreakArea">
<div style="PAGE-BREAK-AFTER: always" id="DSPFPageBreak">
<hr style="BORDER-RIGHT-WIDTH: 0px; BACKGROUND-COLOR: #000000; MARGIN: 4px 0px; 
WIDTH: 100%; BORDER-TOP-WIDTH: 0px; BORDER-BOTTOM-WIDTH: 0px; HEIGHT: 2px; 
COLOR: #000000; CLEAR: both; BORDER-LEFT-WIDTH: 0px" noshade="noshade">
</div>
</div>
<div style="TEXT-ALIGN: center; LINE-HEIGHT: 12.55pt; MARGIN-TOP: 12pt; FONT-
FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">SIGNATURES</div>
<div style="TEXT-ALIGN: justify; LINE-HEIGHT: 12.55pt; MARGIN-TOP: 12pt; FONT-
FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Pursuant to the requirements of the 
Securities Exchange Act of 1934, the registrant has duly caused this report to 
be signed on its behalf by the undersigned, thereunto duly authorized.</div>
<div style="TEXT-ALIGN: justify; LINE-HEIGHT: 12.55pt; MARGIN-TOP: 12pt; FONT-
FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">RepliCel Life 
Sciences Inc.<br style="LINE-HEIGHT: 12.55pt">
</div>
<div style="TEXT-ALIGN: left; LINE-HEIGHT: 12.55pt; FONT-FAMILY: 'Times New 
Roman'; FONT-SIZE: 10pt"><u>/s/ Lee
Buckler&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&
#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#1
60;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160
;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </u></div>
<div style="TEXT-ALIGN: left; LINE-HEIGHT: 12.55pt; FONT-FAMILY: 'Times New 
Roman'; FONT-SIZE: 10pt">Lee Buckler, President &amp; CEO</div>
<div style="TEXT-ALIGN: left; LINE-HEIGHT: 12.55pt; FONT-FAMILY: 'Times New 
Roman'; FONT-SIZE: 10pt">Date:&#160; August 9, 2016</div>
<div style="LINE-HEIGHT: 12.55pt; MARGIN-TOP: 12pt"><br style="LINE-HEIGHT: 
12.55pt">
<hr style="BORDER-BOTTOM: black 4px solid; TEXT-ALIGN: center; BACKGROUND-COLOR:
#ffffff; HEIGHT: 10px; COLOR: #ffffff; MARGIN-LEFT: auto; BORDER-TOP: black 1px 
solid; MARGIN-RIGHT: auto">
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>exh99_1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<html>
<head>
<title></title>
<!--Licensed to: Marketwired
    Document created using EDGARfilings PROfile 4.1.0.0
    Copyright 1995 - 2016 Summit Financial Printing, LLC.  All rights 
reserved.-->
</head>
<body style="TEXT-ALIGN: right; FONT-FAMILY: 'Times New Roman', Times, serif; 
FONT-SIZE: 10pt" bgcolor="#ffffff" text="#000000">
<div style="TEXT-ALIGN: left">
<div style="TEXT-ALIGN: right; LINE-HEIGHT: 12.55pt">&#160;</div>
<div style="TEXT-ALIGN: right; LINE-HEIGHT: 12.55pt">
<hr style="BACKGROUND-COLOR: #ffffff; BORDER-BOTTOM: black 1px solid; BORDER-
TOP: black 4px solid; COLOR: #ffffff; HEIGHT: 10px; MARGIN-LEFT: auto; MARGIN-
RIGHT: auto; text-align: center; TEXT-ALIGN: center">
<font style="FONT-WEIGHT: bold"><a name="Exhibit99.1"><!--Anchor--></a>Exhibit 
99.1</font><br style="LINE-HEIGHT: 12.55pt">
</div>
<div style="LINE-HEIGHT: 13.7pt"><br style="LINE-HEIGHT: 13.7pt">
</div>
<div style="TEXT-ALIGN: center; LINE-HEIGHT: 13.7pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">REPLICEL LIFE SCIENCES
SHARE CONSOLIDATION APPROVED</div>
<div style="LINE-HEIGHT: 12.55pt"><br style="LINE-HEIGHT: 12.55pt">
</div>
<div style="TEXT-ALIGN: center; LINE-HEIGHT: 12.55pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Capital Structure 
Restructuring Expected to Lead to Financing and Milestones</div>
<div style="LINE-HEIGHT: 12.55pt"><br style="LINE-HEIGHT: 12.55pt">
</div>
<div style="TEXT-ALIGN: justify; LINE-HEIGHT: 12.55pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New 
Roman', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">VANCOUVER, BC &#8211; 
August 9, 2016 &#8211; RepliCel Life Sciences Inc. </font>("<font style="FONT-
FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: 
bold">RepliCel</font>" or the "<font style="FONT-FAMILY: 'Times New Roman', 
Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Company</font>") <font 
style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt; FONT-
WEIGHT: bold">(OTCQB: REPCF) (TSXV: RP) (Frankfurt: P6P1)</font><font 
style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 
10pt">,</font><font style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-
SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font>a clinical stage regenerative 
medicine company focused on the development of autologous cell therapies, 
announced today that, further to its News Release of July 22, 2016, the TSX 
Venture Exchange has approved the consolidation of the common shares of the 
Company (each, a "<font style="FONT-FAMILY: 'Times New Roman', Times, serif; 
FONT-SIZE: 10pt; FONT-WEIGHT: bold">Share</font>")<font style="FONT-FAMILY: 
'Times New Roman', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: 
bold">&#160;</font>on the basis of ten (10) pre-consolidation Shares for one (1)
post-consolidation Share (the&#160;"<font style="FONT-FAMILY: 'Times New Roman',
Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Consolidation</font>").&#160; 
The Consolidation will become effective at the opening of the market on 
Wednesday, August 10, 2016.&#160; The Company's symbol shall remain as 
"RP".&#160;</div>
<div style="LINE-HEIGHT: 12.55pt"><br style="LINE-HEIGHT: 12.55pt">
</div>
<div style="TEXT-ALIGN: justify; LINE-HEIGHT: 12.55pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; FONT-SIZE: 10pt">Currently, a total of 67,261,629 Shares 
are issued and outstanding. Accordingly, upon the Consolidation becoming 
effective, a total of 6,726,162 <font style="FONT-FAMILY: 'Times New Roman', 
Times, serif; FONT-SIZE: 10pt">&#160;</font>Shares, subject to adjustments for 
rounding, will be issued and outstanding. There is no maximum number of 
authorized Shares. Computershare Investor Services Inc. ("<font style="FONT-
FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: 
bold">Computershare</font>") will mail letters of transmittal to the 
shareholders providing instructions on exchanging pre-Consolidation share 
certificates for post-Consolidation share certificates.&#160; Shareholders are 
encouraged to send their share certificates, together with their letter of 
transmittal, to Computershare in accordance with the instructions in the letter 
of transmittal.</div>
<div style="LINE-HEIGHT: 12.55pt"><br style="LINE-HEIGHT: 12.55pt">
</div>
<div style="TEXT-ALIGN: justify; LINE-HEIGHT: 12.55pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; FONT-SIZE: 10pt">"As stated in our July 22nd news 
release," stated RepliCel's President and CEO, R. Lee Buckler, "this 
Consolidation is a continuation of the restructuring initiated by the Company in
April and to be finalized with a financing that is expected to be announced 
shortly. We have worked hard to ensure we match our programs, expenses, and 
expected financing to ensure we have sufficient capital to move the Company 
through several significant milestones in the months ahead."</div>
<div style="LINE-HEIGHT: 12.55pt"><br style="LINE-HEIGHT: 12.55pt">
</div>
<div style="TEXT-ALIGN: justify; LINE-HEIGHT: 12.55pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; FONT-SIZE: 10pt">The Company recently announced the launch
of the next phase clinical testing of its RCH-01 product in Japan sponsored by 
its licensee, Shiseido Company, and expects two clinical data milestones within
the next six months, namely data from its phase 1/2 clinical trial of RCT-01 for
the treatment of chronic Achilles tendinopathy and data from its phase 1 
clinical trial of RCS-01 for the treatment of aging and sun-damaged skin. The 
Company also has the opportunity to complete the building and validation testing
of the commercial-grade prototypes of its next-generation dermal injector 
devices which could be market-ready and the subject of a licensing deal by late 
2017.</div>
<div style="TEXT-ALIGN: justify; LINE-HEIGHT: 12.55pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; FONT-SIZE: 10pt">&#160;</div>
<div style="TEXT-ALIGN: justify; LINE-HEIGHT: 12.55pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; FONT-SIZE: 10pt"><u style="FONT-WEIGHT: bold">About 
RepliCel Life Sciences</u></div>
<div style="TEXT-ALIGN: justify; LINE-HEIGHT: 12.55pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; FONT-SIZE: 10pt">RepliCel is a regenerative medicine 
company focused on developing autologous cell therapies that address conditions 
caused by a deficit of healthy cells required for normal healing and function. 
The Company's product pipeline is comprised of two ongoing clinical trials (RCT-
01: tendon repair and RCS-01: skin rejuvenation) as well as its RCH-01: hair 
restoration product under exclusive license by Shiseido Company for certain 
Asian countries. All product candidates are based on RepliCel's innovative 
technology utilizing cell populations isolated from a patient's healthy hair 
follicles. The Company has also developed a propriety injection device (RCI-02) 
optimized for the administration of its products and licensable for use with 
other dermatology applications.</div>
<div style="LINE-HEIGHT: 12.55pt"><br style="LINE-HEIGHT: 12.55pt">
</div>
<div style="TEXT-ALIGN: left; LINE-HEIGHT: 12.55pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; FONT-SIZE: 10pt">Please visit www.replicel.com for 
additional information.</div>
<div style="TEXT-ALIGN: justify; LINE-HEIGHT: 12.55pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; FONT-SIZE: 10pt">&#160;</div>
<div style="MARGIN-TOP: 10pt; MARGIN-BOTTOM: 10pt; CLEAR: both" 
id="DSPFPageBreakArea">
<div style="PAGE-BREAK-AFTER: always" id="DSPFPageBreak">
<hr style="BORDER-RIGHT-WIDTH: 0px; BACKGROUND-COLOR: #000000; MARGIN: 4px 0px; 
WIDTH: 100%; BORDER-TOP-WIDTH: 0px; BORDER-BOTTOM-WIDTH: 0px; HEIGHT: 2px; 
COLOR: #000000; CLEAR: both; BORDER-LEFT-WIDTH: 0px" noshade="noshade">
</div>
</div>
<div style="LINE-HEIGHT: 12.55pt"><br style="LINE-HEIGHT: 12.55pt">
</div>
<div style="TEXT-ALIGN: justify; LINE-HEIGHT: 12.55pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">For more information, 
please contact:</div>
<div style="LINE-HEIGHT: 12.55pt"><br style="LINE-HEIGHT: 12.55pt">
</div>
<div style="TEXT-ALIGN: justify; LINE-HEIGHT: 12.55pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">CORPORATE/INVESTOR 
RELATIONS:</div>
<div style="TEXT-ALIGN: justify; LINE-HEIGHT: 12.55pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; FONT-SIZE: 10pt">R. Lee Buckler, President &amp; CEO</div>
<div style="TEXT-ALIGN: justify; LINE-HEIGHT: 12.55pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; FONT-SIZE: 10pt">Telephone: 604-248-8693</div>
<div style="TEXT-ALIGN: left; LINE-HEIGHT: 12.55pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; FONT-SIZE: 10pt">Email: lee@replicel.com</div>
<div style="LINE-HEIGHT: 12.55pt"><br style="LINE-HEIGHT: 12.55pt">
</div>
<div style="TEXT-ALIGN: justify; LINE-HEIGHT: 12.55pt; FONT-STYLE: italic; FONT-
FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">Neither the TSX 
Venture Exchange nor its Regulation Services Provider (as that term is defined 
in policies of the TSX Venture Exchange) accepts responsibility for the adequacy
or accuracy of this release.</div>
<div style="LINE-HEIGHT: 12.55pt"><br style="LINE-HEIGHT: 12.55pt">
</div>
<div style="TEXT-ALIGN: justify; LINE-HEIGHT: 12.55pt; FONT-STYLE: italic; FONT-
FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt; MARGIN-RIGHT: 
9.35pt">This press release contains forward-looking information that involve 
various risks and uncertainties regarding future events. Such forward-looking 
information can include without limitation statements based on current 
expectations involving a number of risks and uncertainties and are not 
guarantees of future performance of RepliCel, such as statements regarding the 
Company's<font style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 
10pt">&#160;</font>ability to complete a financing and the two clinical data 
milestones within the next six months and its ability to complete the building 
and validation testing of the commercial-grade prototypes of its next-generation
dermal injector devices which could be market-ready and the subject of a 
licensing deal by late 2017. Such forward-looking statements and information are
based on current expectations involving a number of risks and uncertainties and 
are not guarantees of future performance of RepliCel. There are numerous risks 
and uncertainties that could cause actual results and RepliCel's plans and 
objectives to differ materially from those expressed in the forward-looking 
information, including: failure to obtain CE mark clearance or necessary 
regulatory approvals; delays enrolling clinical trial participants; negative 
results from the Company's trials; the effects of government regulation on the 
Company's business; risks associated with the Company's ability to obtain and 
protect rights to its intellectual property; risks and uncertainties associated 
with the Company's ability to raise additional capital; and other factors beyond
the Company's control. Actual results and future events could differ materially 
from those anticipated in such information. These and all subsequent written and
oral forward-looking information are based on estimates and opinions of 
management on the dates they are made and are expressly qualified in their 
entirety by this notice. Except as required by law, RepliCel does not intend to 
update these forward-looking statements.</div>
<div style="LINE-HEIGHT: 12.55pt"><br style="LINE-HEIGHT: 12.55pt">
</div>
<div style="TEXT-ALIGN: left; LINE-HEIGHT: 12.55pt"><br style="LINE-HEIGHT: 
12.55pt">
</div>
<div id="DSPFPageFooter">
<div style="LINE-HEIGHT: 13.7pt">
<hr style="BACKGROUND-COLOR: #ffffff; BORDER-BOTTOM: black 4px solid; BORDER-
TOP: black 1px solid; COLOR: #ffffff; HEIGHT: 10px; MARGIN-LEFT: auto; MARGIN-
RIGHT: auto; text-align: center; TEXT-ALIGN: center">
</div>
</div>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>